Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a prospective observational study to better understand early-onset gastrointestinal EoGI cancer by examining clinical and demographic data, tumor characteristics, and patient lifestyle habits. The study aims to capture a comprehensive picture of this type of cancer in newly diagnosed patients aged 18 to 49 years. This research is carried out across multiple centers in northern Italy, involving diverse hospital settings. Participants include newly diagnosed EoGI cancer patients confirmed by histology, covering colorectal, gastroesophageal, and pancreatic tumors at any disease stage. The study does not alter any cancer treatments patients receive, which continue as per best clinical practice. Researchers focus on collecting detailed patient data without influencing treatment decisions. During the study, participants provide information on their medical history and lifestyle, which researchers use to characterize the cancer features and patient habits. Follow-up assessments occur at six months, one year, and two years to monitor outcomes. The primary outcome is measured one year from enrollment. The total participation duration extends up to two years, with no additional treatment provided by the study.
Actively Recruiting
Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.
Actively Recruiting
This observational study investigates the impact of surgical centralization and treatment strategies on oncologic outcomes in female patients diagnosed with epithelial ovarian cancer EOC between 2018 and 2023 within the Emilia-Romagna region in Italy. The study aims to compare progression-free survival and overall survival across three time periods before centralization and the COVID-19 pandemic, during the pandemic peak, and during the post-pandemic control phase. This research is conducted by the AUSL-IRCCS of Reggio Emilia and includes both retrospective and prospective components. Participants are grouped based on when they received treatment prior to centralization and the pandemic 2018-2019, during the peak pandemic with changes in care due to resource limitations 2020-2021, and after the pandemic peak reflecting new care standards 2022-2023. No experimental treatments are given, as all patients receive standard care according to routine clinical practice. The study observes variations in surgical approaches, chemotherapy, and use of therapies like Bevacizumab and PARP inhibitors. Throughout the study, participants clinical records and outcomes are reviewed retrospectively, with ongoing clinical follow-up planned for up to five years. Researchers assess survival rates, treatment types, tumor characteristics, recurrence patterns, and use of secondary treatments including surgery and radiotherapy. Data collection includes information from multidisciplinary tumor boards and patient consents. The study spans until June 2031, allowing comprehensive evaluation of long-term outcomes.
Actively Recruiting
This trial studies patients with early stage Follicular Lymphoma who have not received prior treatment. It is a phase III, multicenter, randomized clinical trial comparing two treatments to evaluate which approach better controls the disease. The study is open label, meaning both patients and researchers know the assigned treatments. The purpose is to assess progression-free survival and other outcomes over several years. Participants are randomly assigned to one of two groups one receives involved-site radiotherapy alone at a standard dose of 24 Gy, and the other receives the same radiotherapy followed by eight doses of Obinutuzumab given intravenously over approximately nine months. The Obinutuzumab doses start with four weekly infusions followed by four infusions every three weeks. This comparison aims to evaluate the potential benefit of adding Obinutuzumab to radiotherapy. During the study, participants undergo PETCT scans for staging and assessments, blood tests including PCR for molecular markers, bone marrow biopsies, and other laboratory tests to monitor response and safety. Researchers measure outcomes such as progression-free survival over 33 months, complete and overall response rates, and event-free survival over up to 45 months. Safety and molecular studies including liquid biopsies and genetic analyses are also performed. Participants are followed for several years to monitor disease status and side effects.
Actively Recruiting
Researchers are collecting real-world data on patients undergoing rotator cuff repair using the REGENETEN Bioinductive Implant System. This prospective, single-arm, multicenter registry involves up to 50 centers across the United Kingdom, Europe, and Australia, aiming to enroll up to 400 patients. The study focuses on evaluating clinical and health economic outcomes after surgery for rotator cuff injuries. Participants receive arthroscopic rotator cuff repair surgery augmented with the REGENETEN Bioinductive Implant, a device designed to manage and protect tendon injuries without substantial tendon tissue loss. Patients are treated according to standard medical care, and the study gathers data on their recovery and outcomes over time. Participants will be monitored up to two years after surgery with regular assessments including quality of life, arm and shoulder function, pain levels, and shoulder-specific scores at baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months. Additional data on retear rates, postoperative recovery, sling use, mobilization time, and return to work are also collected. The study provides long-term insight into patient progress following the use of the implant.
Actively Recruiting
Researchers are investigating the relationship between MYC gene changes, lymphoma genetic mutations, and the immune environment in adults with Diffuse Large B-cell Lymphoma DLBCL or High-Grade B-cell Lymphoma HGBCL. These lymphomas are diverse diseases making up over a third of adult lymphomas, with survival rates of around 60-70% over five years. The study aims to better understand these genetic factors and their impact on disease outcomes to improve treatment approaches. This observational study includes patients diagnosed with DLBCL or HGBCL who have MYC gene rearrangements or increased MYC gene copies. Participants have received standard first-line chemotherapy treatments such as R-CHOP or intensified regimens. The study collects data retrospectively and prospectively to explore genetic markers, immune cell patterns, and clinical outcomes related to these MYC changes and other genetic alterations. Participants provide tissue samples and clinical information, which researchers analyze for genetic and histological features. The study evaluates how these factors relate to patient responses and survival over up to 36 months. Researchers also review treatment types, risk of disease recurrence, and the effectiveness of preventive therapies. The study spans from diagnosis after January 2019 through long-term follow-up, helping to identify potential prognostic and predictive markers in lymphoma.
Actively Recruiting
Researchers are evaluating the impact of a healthy lifestyle implemented Survivorship Care Plan LS-SCP on the quality of life in long-term lymphoma survivors who have been in remission for at least 3 years and up to 10 years. This is a prospective, randomized, open-label, multicenter study involving two groups to compare the effects of the lifestyle plan versus standard follow-up care. Participants in the experimental group will follow a Survivorship Care Plan that includes nutritional guidance and physical activity recommendations for 6 months. Compliance with this plan will be monitored through automatic bi-monthly phone calls. The control group will receive no specific intervention and will continue with usual clinical follow-up, completing questionnaires at 6 and 12 months after randomization. During the study, all participants will complete validated questionnaires assessing quality of life, fatigue, anxiety, depression, and other health aspects at baseline, 6 months, and 12 months. Clinical assessments and evaluations of metabolic and cardiovascular outcomes, cognitive function, and adherence to healthy lifestyles will also be conducted. The main outcome measured is the global quality of life over a period of up to 30 months from the study start.
Actively Recruiting
This research aims to evaluate the effects of adding Vitamin D supplementation to standard immunochemotherapy in elderly patients diagnosed with Diffuse Large B-Cell Lymphoma or Follicular grade IIIb lymphoma. This open-label, randomized phase III trial compares two treatment approaches to understand whether Vitamin D affects outcomes in patients aged 65 and older undergoing immunochemotherapy. Participants are randomly assigned to one of two groups. Both groups receive a prephase of oral prednisone followed by six cycles of immunochemotherapy with R-CHOP or R-miniCHOP every 21 days. The experimental group also receives Vitamin D supplementation starting before treatment and continuing through immunochemotherapy according to a set schedule, including loading doses based on baseline Vitamin D levels and weekly maintenance. Patients may continue Vitamin D supplementation after treatment for up to two years. During the study, participants undergo baseline assessments and are monitored regularly through the treatment cycles. Researchers track progression-free survival over 54 months as the primary outcome, along with overall survival, response rates, Vitamin D levels, physical functioning, and fatigue. Safety and treatment adherence are also monitored, with follow-up visits extending up to several years to evaluate long-term outcomes.
Actively Recruiting
Researchers are collecting safety and performance data on the PRESERFLO MicroShunt XI device in patients with primary open angle glaucoma whose intraocular pressure IOP is not adequately controlled despite maximum tolerated medical therapy. This study focuses on patients with IOP between 18 and 35 mmHg or those whose glaucoma progression requires surgery. The study is a prospective, multicenter, single-arm post-market follow-up to evaluate this CE-marked device designed for glaucoma treatment. The PRESERFLO MicroShunt XI is a small implantable device that creates a passageway to drain aqueous humor from the eyes anterior chamber to a bleb beneath the conjunctiva, helping to reduce eye pressure. The device is surgically implanted by trained ophthalmologists or surgeons specializing in glaucoma or anterior segment surgery. There is no control group, and no biospecimens are collected as part of this study. Participants will undergo surgical implantation of the MicroShunt XI and be followed over time to monitor safety and performance. Researchers will assess changes in intraocular pressure up to 12 months after surgery. No additional ocular surgeries are planned during the study period. The study includes regular visits to evaluate eye health, monitor adverse events, and collect performance data, with participant involvement lasting up to 12 months.